Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bermudez, Lidia
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia	Recruiting	3	405	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
Cueto, Felix
MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia	Recruiting	3	1328	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Hypertriglyceridemia	07/26	10/26
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia	Recruiting	3	405	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26
Ravelo, Elizabeth
SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia	Recruiting	3	405	Europe, Canada, US, RoW	Plozasiran Injection, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Severe Hypertriglyceridemia	07/26	10/26